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Obesity is a major public health issue as it enhances the risk of suﬀering several chronic diseases of increasing prevalence.
Obesity results from an imbalance between energy intake and expenditure, associated with a chronic low-grade inﬂammation.
Gut microbes are considered to contribute to body weight regulation and related disorders by inﬂuencing metabolic and immune
host functions. The gut microbiota as a whole improves the host’s ability to extract and store energy from the diet leading to
body weight gain, while speciﬁc commensal microbes seem to exert beneﬁcial eﬀects on bile salt, lipoprotein, and cholesterol
metabolism. The gut microbiota and some probiotics also regulate immune functions, protecting the host form infections and
chronic inﬂammation. In contrast, dysbiosis and endotoxaemia may be inﬂammatory factors responsible for developing insulin
resistance and body weight gain. In the light of the link between the gut microbiota, metabolism, and immunity, the use of dietary
strategies to modulate microbiota composition is likely to be eﬀective in controlling metabolic disorders. Although so far only a
few preclinical and clinical trials have demonstrated the eﬀects of speciﬁc gut microbes and prebiotics on biological markers of
these disorders, the ﬁndings indicate that advances in this ﬁeld could be of value in the struggle against obesity and its associated-
metabolic disorders.
Copyright © 2008 Yolanda Sanz et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Obesity is a major public health concern aﬀecting both the
developed and the developing world. The obesity epidemic
started to grow in US in the 1980s, with values rising from
22.9% obese adults in 1988–1994 to 30.5% in 1999–2000 [1].
In 1996, the World Health Organization (WHO) together
with national Ministries of Health agreed to tackle obesity
worldwide, but since then it has increased sharply, reaching
values of at least 20% obese adults in most US states and
European countries [2]. Obesity is detrimental to the quality
of life and implies high health costs as a consequence of
its associated morbidities. Overweight and obesity constitute
risk factors for a number of chronic diseases including
diabetes, cardiovascular diseases, nonalcoholic fatty liver
disease, cancer, and other immune-related disorders such as
asthma and infections [3].
Obesity results from a long-term positive imbalance
between energy intake and expenditure with excessive
increase in body fat. Obesity and the associated disorders are
also characterized by a state of chronic, low-grade inﬂam-
mation with abnormal cytokine and adipokine production
[4]. Production of inﬂammatory immune mediators such
as tumor-necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β,
CC-chemokine ligand 2 (CCL2 or monocyte chemotactic
protein 1), and the proinﬂammatory adipokines leptin and
resistin is usually high in these subjects, whereas production
of the anti-inﬂammatory and insulin-sensitizing adipokine
adiponectin is reduced [5]. Inﬂammation associated with
obesity involves diverse signal transduction cascades includ-
ing the nuclear factor kappa B (NF-κB)/IKKβ system and
the Jun N-terminal kinase (JNK) [4, 6]. Leptin is the
dominant long-term signal informing the brain of energy
stores and, together with insulin, is secreted upon ingestion
thus inhibiting food intake. However, human obesity is not
commonly associated with leptin-deﬁciency but with leptin-
resistance and increased levels of this adipokine. Leptin
seems to exert a proinﬂammatory eﬀect by inducing the
production of CCL2, proinﬂammatory cytokines (TNF-α,
IL-6, and IL-12), and also typical T helper (Th) 1-cytokines
(IL-2 and IFNγ) involved in other chronic inﬂammatory and
autoimmune disorders such as Crohn’s disease [6, 7].2 Interdisciplinary Perspectives on Infectious Diseases
Although susceptibility to deﬁnitive increases in body
weight is genetically determined, the environment also
inﬂuences weight gain considerably. It is currently believed
that macrosocial changes associated with regular intake of
energy-dense foods and low-physical activity have created
an obesogenic environment worldwide, constituting the
cornerstone of the global obesity epidemic [8]. Traditional
treatments based on calorie-restricted diets and increased
physical activity have succeeded in controlling obesity to
some extent [9]. Nevertheless, these strategies usually yield
limited and short-lived weight reductions and most people
regain some of their weight loss [3]. Neither has pharmaco-
logical therapy fully succeeded in eﬀectively treating obesity
for long-term periods and also has a number of side-eﬀects
[3, 10]. In this scenario, the identiﬁcation of additional envi-
ronmental factors involved in energy regulation is critical
with a view to develop more eﬃcient intervention strategies.
The human gut is populated by an array of bacterial
species that coevolve with the host since birth and maintain
dynamic interactions with each other throughout life. The
collective genome (microbiome) of the gut microbiota
contains at least 100 times as many genes as the human
genome, with most serving human physiological functions
[11]. The metabolic role of the gut microbiota is essential
to the biochemical activity of the human body, resulting
in salvage of energy, generation of absorbable compounds,
and production of vitamins and other essential nutrients
[12]. Thus, humans are considered superorganisms whose
metabolism represents the combination of both microbial
and human features [11]. The gut microbiota also regulates
many aspects of innate and acquired immunity, protecting
the host from pathogen invasion and chronic inﬂammation
[13, 14]. In contrast, imbalances in the composition of
gut microbiota have been associated with susceptibility to
infections, immune-based disorders, and recently also with
insulin resistance and body weight gain [15]. In the last
decades, sound relationships between the composition of
the gut microbiota and human health have been established,
leading to the design of dietary strategies to favor the
prevalence of beneﬁcial bacteria to maintain a healthy
status. These strategies include the administration of pre-
biotic oligosaccharides, which stimulate the growth and/or
metabolic activity of beneﬁcial bacteria, and also of selected
bacterial strains (probiotics) in the form of functional foods
and supplements [16]. Herein, the current knowledge of
the relationships between the composition and functions of
the gut microbiota and obesity is reviewed, including some
studies intended to evaluate the eﬀects of probiotics and
prebiotics in the management of metabolic disorders.
2. GUT MICROBIOTA COMPOSITION, DIET,
AND OBESITY
Obesity has been associated with increases in the relative
abundanceofFirmicutesandproportionalreductionsinBac-
teroidetes by comparisons between the distal gut microbiota
of genetically obese (leptin deﬁcient ob/ob mice) and lean
m i c e ,a sw e l la so ft h a to fo b e s ea n dl e a nh u m a ns u b j e c t s
[17, 18]. In addition, obese human adults submitted to
a hypocaloric diet (either low carbohydrate- or low fat-
containing diet) showed signiﬁcant increases in fecalpropor-
tions of Bacteroidetes paralleled to weight loss over a one-
year-long intervention in a few subjects [18]; nonetheless,
species diversity was reported to remain constant. Studies
on the cecal microbiota of genetically obese mice and their
lean littermates also related a higher proportion of Archaea
to obesity [17]. These relationships between obesity and
the gut microbiota composition were ﬁrst based on DNA
sequence analysis of the total distal gut microbiome of mice
and humans obtained from genomic libraries or directly
by pyrosequencing. Of these microbial groups, Bacteroidetes
and Firmicutes constitute the dominant bacterial subdivision
(>99%) among the 70 bacterial subdivisions identiﬁed in
distal gut, while Methanobrevibacterium smithii constitutes
the most prominent methanogenic archaeon among the 13
Archaea divisions reported to date based on 16S ribosomal
DNA sequencing data [11]. More recently, diet-induced
obesity in animal models has been associated with increases
in the proportion of a single-uncultured clade within the
Mollicutes class of Firmicutes, which was also diminished
by subsequent dietary manipulations to limit weight gain,
showing more speciﬁc relationships between obesity and
components of the gut microbiota [19]. A study of a Chinese
family, comprising 3 males and 4 females, also related the
lowest Bacteroidetes to Firmicutes ratio to the overweight
individual, and demonstrated a high degree of interpersonal
variation in this value, ranging from 0.26 to 1.36 [20].
Diﬀerences in fecal microbiota composition were shown
to predict overweight in children early in life. Children
maintaining normal weight showed a greater number of
biﬁdobacteria, while children becoming overweight showed
a greater number of Staphylococcus aureus in feces dur-
ing infancy [21]. Although the selected population group
included children prone to allergy, who may show the
described microbial aberrancies, the obtained results are
also in accordance with the protective role attributed to
breast-milk against developing obesity later in life [22], and
the predominance of biﬁdobacteria in the gut of breastfed
babies [23]. Shifts in composition of animal and human gut
bacteria in response to dietary changes (a high protein/low
carbohydrate or high-fat intake) have also been shown to
altermicrobialcompositionandactivityinthelargeintestine
that, in turn, could exert an impact on health [15, 24].
Obese humans submitted to a dietary intervention, based
on reducing carbohydrate intake and increasing protein
intake, showed reductions in populations of Biﬁdobacterium,
and Roseburia spp. and Eubacterium rectale subgroups
of clostridial cluster XIVa when carbohydrate intake was
decreased, while no diﬀerences were detected in Bacteroides
orotherclostridialclusters[24].TheabundanceofRoseburia
spp. and E. rectale group correlated well with the decline in
fecal butyrate as carbohydrate intake was reduced; however,
relationships to body weight were not established. Recent
studies on the evolution of mammals and their gut microbes
pointed out that the acquisition of a new diet is a funda-
mental driver for changes in gut bacterial diversity, which
increases from carnivory to omnivory to herbivory [25].
Alterations in gut microbiota composition associated withYolanda Sanz et al. 3
genetic or diet-induced obesity have also been shown to be
reversible by oral transfer of the gut microbiota from lean
micetoagerm-freerecipient[19,26]orbyadministrationof
prebioticsubstratestoanimalmodelsatleastovershort-term
periods [27]. Therefore, it seems likely that a combination of
environmental (e.g. diet) and genetic factors contributes to
deﬁning unique combinations of bacteria within an individ-
ual, which could favor either an obese or lean phenotype. In
this context, some authors argue that both antibiotics and
probiotics have demonstrated to act as growth promoters
whenusedinanimalfeedingand,therefore,couldcontribute
to current human obesity [28]. However, while antibiotics
reduce gut microbiota populations, probiotics restores their
levels. Therefore, their common eﬀect on animal weight
gain can be only a consequence of their common role in
preventing infections. By contrast, other scientists consider
that the intentional manipulation of the composition of
gut microbiota via dietary strategies is a possible tool to
revert or prevent overweight and particularly metabolic-
associated disorders [19, 26, 27]. Although this line of
research is still in its infancy, in the following sections we
summarize current evidence on the mechanisms of action of
gut microbiota on metabolic and immune aspects of obesity
andtheconsequencesofitsdietarymanipulationbypro-and
prebiotics.
3. INFLUENCE OF THE GUT MICROBIOTA ON
ENERGY METABOLISM
The gut microbiota is considered a critical factor, together
with lifestyle, involved in energy metabolism and obesity.
Germ-free mice colonized by the distal gut microbiota of
conventionally raised mice produced a remarkable increase
(60%) in body fat within 10–14 days, although feed con-
sumption was reduced compared to the control germ-free
mice [29]. This process also stimulated the synthesis of lep-
tin,andproducedfasterglycemiaandinsulinemia,paralleled
to body-fat increase [29]. The microbial colonization was
demonstrated to increase the host’s ability to both harvest
energy from the diet and store this energy in adypocites. This
is thought to be achieved by diverse mechanisms including
improvement of diet macronutrient utilization, generation
of metabolites involved in energy balance and regulation of
host gene expression. Commensal bacteria have specialized
sets of hydrolyses and transporters to digest nutrients,
like complex polysaccharides, that would, otherwise, be
inaccessible to humans. These are the main energy sources
for bacteria colonizing the large intestine and confer them a
competitive advantage over transient bacteria. The microbial
fermentation of undigested dietary compounds can provide
approximately 10% of the daily energy supply in omnivores
and up to 70% in herbivores [30]. The degradation of
matrix and other dietary polysaccharides (xylans, manans,
pectins, starch, and inulin) as well as host mucins lead to
the generation of intermediate products (lactate, succinate,
etc.) and ﬁnally short-chain fatty acids (SCFA), including
butyrate, acetate, and propionate, which are almost com-
pletely absorbed along the gastrointestinal tract (Figure 1).
The ability to degrade highly insoluble polymeric substrates,
suchascelluloseandmucin,seemstobelimitedtoasubsetof
primarymicrobedegradersinthelargeintestineandrequires
the expression of speciﬁc substrate attachment, degradation,
and uptake systems like the so-called cellulosome complex.
In fact, cellulolytic species have been shown to form bioﬁlm
associations with plant surfaces in vitro, integrated by a
higher fraction of Firmicutes and a smaller fraction of
Bacteroides, which suggests a more prominent role of the
former bacterial group in energy harvest from the diet by
facilitating complex polysaccharide utilization [31]. Several
clostridial clusters of Firmicutes are important butyrate-
producing bacteria in the distal gut, such as Roseburia,
E. rectale, Eubacterium halli, and Anaerostipes caccae, most
of which are included in clostridial cluster XIVa [31].
Acetogenesis is another metabolic attribute of relevance to
obesity identiﬁed in this clostridial cluster [31], which could
partly explain the inverse relationship between Firrmicutes
and body weight reductions in previous human intervention
studies [18]. Soluble and less complex oligosaccharides such
as starch and fructooligosaccharides can be utilized by other
gut microbes such as Bacteroides and Biﬁdobacterium, which
could also contribute to the generation of intermediary
metabolites and ﬁnally to SCFA (Figure 1).
Although butyrate-producing bacteria would appear
to be related to higher gut metabolic activity leading to
overweight, butyrate is extensively utilized by enterocytes
and generally regarded as a healthy metabolite [32]. The
main role of butyrate is to fuel enterocytes, covering up to
70% of their energy needs and contributing to epithelial cell
growth regulation and diﬀerentiation (Figure 1). Butyrate
alsoexertsanti-inﬂammatoryeﬀectsandseemstocontribute
to glucagon-like peptide 1 (GLP-1) generation, which is
involved in satiety, by promoting diﬀerentiation of stem
cells into positive GLP-1 L cells. Altogether, this may have
beneﬁcial eﬀects on obese-prone subjects [32, 33]. Unlike
butyrate, acetate and propionate generated in intestinal
lumen can reach the blood stream and the liver through the
portal vein (Figure 1). Acetate can contribute to lipid and
cholesterol synthesis in the liver by activating the cytosolic
acetyl S CoA synthetase 2, while propionate may inhibit lipid
synthesis from acetate at least in rat hepatocytes [34]. In
fact, high-propionate production through fermentation of
starch or fructans has been associated with serum and liver
cholesterol reduction in rats and the acetate to propionate
ratio in portal blood, proposed as a possible maker of
the eﬀects of these dietary ingredients on lipid metabolism
[35, 36]. Nevertheless, acetate administered at a high dose
to rats and rat hepatocytes also induced AMP kinase
and/or reduced SREBP-1c expression related to lipogenesis
inhibition, therefore further studies should be carried out in
humans to verify its positive or negative inﬂuences on lipid
metabolism [37].
In addition to SCFA, hydrogen is produced by
polysaccharide-degrading species and its further utilization
by methanogens, acetogens and sulfate-reducing gut
microbes also activates the metabolism and growth of
polysaccharide-degrading bacteria (Figure 1). Archaea,
which are the main gut methanogenic microorganisms,
were also overrepresented in genetically obese mice as4 Interdisciplinary Perspectives on Infectious Diseases
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Figure 1: Schematic diagram of the main metabolic pathways of dietary poly- and oligosaccharides in the gut ecosystem.
compared to their lean littermates and were related to a
greater capacity to promote adiposity when transferred to
germ-free recipients [38]. Eubacterium dolichum,ah u m a n
Mollicute, was also shown to favor import and processing of
simple sugars in subjects under a Western-style diet, partly
explainingitsassociationandthatofFirmicutes divisionwith
obesity [19]. In addition, cross-feeding mechanisms between
components of the gut microbiota have been identiﬁed at
diﬀerent stages of the utilization of complex energy-rich
polysaccharides. Thus, B. adolescentis can degrade starch,
generating intermediate products (lactate and acetate)
that can be utilized by butyrate-forming bacteria such as
E. hallii to generate butyrate [39] or by other intestinal
bacterial groups that convert lactate into propionate by
the acrylate pathway [40]. Coinoculation of M. smithii and
B. thetaiotaomicron into germ-free mice showed that M.
smithii directs B. thetaiotaomicron to focus on fermentation
of dietary fructans to acetate, whereas B. thetaiotaomicron-
derived formate is used by M. smithii for methanogenesis.
Moreover, B. thetaiotaomicron-M. smithii cocolonization
produced a signiﬁcant increase in host adiposity compared
with monoassociated, or B. thetaiotaomicron-D. piger
biassociated animals [41]. These studies emphasize the
role of interactive sets of microbes, rather than the role
of individual microorganism within the gut ecosystem in
energy-metabolism and body weight regulation. This makes
it far more complex to identify those that are critical to
obesity control through dietary strategies.
The gut microbiota may also inﬂuence energy balance
by modifying gene expression of host-related metabolic
functions. Angiogenesis, which is primarily involved in
distributing nutrients to peripheral tissues, was shown to
depend on the gut microbial colonization process. Although
capillary network formation was arrested in adult germ-
free mice, this developmental process restarted and was
completed within 10 days after colonization with a complete
microbiota harvested from conventionally raised mice, or
with Bacteroides thetaiotaomicron [42]. Commensal bacteria,
such as B. thetaiotaomicron, have also been shown to
induce expression of host monosaccharide transporters in
monocolonized mice [43]. This would lead to increasing
the absorption of monosaccharides and SCFA and, thereby,
promote the novo synthesis of lipids in the liver. In addition,
the microbial colonization of germ-free mice increased liver
expression of two key enzymes involved in the de novo
fatty acid biosynthetic pathways, acetyl-CoA carboxylase and
fatty acid synthase, as well as the transcriptional factors
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lipogenic responses to insulin and glucose [29]. Unlike
colonized mice, germ-free animals were protected against
the obesity that develops after consuming a Western-style,
high-fat, sugar-rich diet by increasing fatty acid metabolism
via two complementary mechanisms: (i) increasing levels
of circulating fasting-induced adipose factor (Fiaf), which
inhibits lipoprotein lipase thereby limiting fat storage in
adipocytes and promoting fat oxidation in muscle; and (ii)
increasing skeletal muscle and liver levels of phosphorylated
AMP-activated protein kinase and its downstream targets,
involved in fatty acid β oxidation [44].
Commensal gut microbiota and probiotics could also
regulate serum lipids by taking part in bile acid metabolism.
Bile salts are highly eﬀective detergents that promote solu-
bilization and absorption of dietary lipids throughout the
intestine. The major bile salt modiﬁcations of microbial
origin in the human gut include deconjugation, oxidation
o fd i v e r s eh y d r o x y lg r o u p sa n d7α/β-dehydroxylation [45].
Certain probiotics have been shown to decrease serum
cholesterollevelsbymeansoftheirbilesalthydrolyticactivity
[46].Signiﬁcantbilesalthydrolysisoccurringintheproximal
and terminal ileum reduces bile salt uptake through high-
aﬃnity transport system and lipid solubilization. This also
leads to an increase in bile-acid excretion in feces and bile-
acid synthesis from cholesterol [45]. For example, admin-
istration of L. acidophilus ATCC 43121 seemed to reduce
serum cholesterol levels by bile acid deconjugation and
dehydroxylation reactions during cholesterol metabolism in
hypercholesterolemia-induced rats [46]. This intervention
resulted in increased excretion of total fecal acid sterols and
secondary bile acids (deoxycholic and lithocholic acids), and
a reduction of primary bile acids (cholic and chenodeoxy-
cholic acids). Particularly, the reduction in blood cholesterol
levels was related to the increase in the insoluble bile acid,
lithocholic acid. More recently, metabolomic studies have
indicated that supplementation of Lactobacillus paracasei
NCC2461 or Lactobacillus rhamnosus NCC4007 probiotics
to germ-free mice colonized with human baby ﬂora-induced
changes in hepatic-lipid metabolism and enterohepatic
recirculation of bile acids that led to a decrease in the
plasma concentrations of lipoproteins VLDL and LDL, when
compared to controls [47]. Lactobacillus supplementation
also decreased fecal excretion of bile acids probably due to
their accumulation in Lactobacillus probiotic cells. Probiotic
administration also led to reductions of acetate in cecal
content as well as of the hepatic acetate to propionate ratio,
which was related to a reduction in serum lipids [47].
Furthermore, studies in vitro indicated that fecal commensal
bacteria, but not probiotics, were able to reduce cholesterol
to coprostanol and thus increasing its excretion in feces [48].
Some probiotic strains of the genus Lactobacillus and
Biﬁdobacterium were also reported to synthesize conjugated
linolenic acid (CLA) from polyunsaturated fatty acids of soy
oil, which reduces serum lipids and cholesterol in liver. One
example of these bacteria is Lactobacillus rhamnosus PL60,
which is a human isolate that produces t10, c12-conjugated
linoleic acid and was found to exert an antiobesity eﬀect on
diet-induced obese mice after 8 weeks of feeding. This strain
reduced body weight without reducing energy intake, and
caused a speciﬁc reduction of white adipose tissue without
producing liver steatosis, which is a common side eﬀect of
CLA [49].
4. IMMUNE ROLE OF THE GUT MICROBIOTA
AND OBESITY
Obesity is considered an inﬂammatory disorder, which
aﬀects both innate and adaptive immunity and favors the
development of other disorders such as type-2 diabetes and
cardiovascular diseases [50]. In fact, chronic activation of
innate immunity is regarded as a risk factor as it favors the
development of these disorders, which could also be inﬂu-
enced by the gut microbiota [27, 51]. The gut microbiota
largely regulates innate and adaptive immunity, inﬂuencing
local and systemic responses (Figure 2). The recognition of
bacterial components through pattern-recognition receptors
(PRRs), such as toll-like receptors (TLRs) of innate immune
cells, is considered to be the starting point of immunity,
informing the immunocompetent cells to respond properly
to each environmental stimulus (e.g., pathogens or harm-
less microbes) [13]. TLR-4 recognizes lipopolysaccharide
(LPS) from Gram-negative bacteria, while TLR-2 recognizes
lipopeptides and lipoproteins from various pathogens, and
peptidoglycan and lipoteichoic acid from Gram-positive
bacteria (Figure 2)[ 52]. Upon ligand binding, TLR inter-
acts with diﬀerent adaptor proteins (MyD88, TIRAP/Mal,
TRIF, and TRAM) activating the transcription of diﬀerent
downstream eﬀector systems, such as the mitogen-activated
kinases (MAPK), the NF-κB/IKKβ system, and the activator
protein-1 (AP-1) with production of cytokines and diverse
immune mediators [53]. Cytokines such as TNF-α,I L - 1 β,
andIL-6arethemajorproinﬂammatorymediatorsproduced
in response to TLR-4 stimulation by endotoxin (LPS) as well
as those increased in obese and insulin-resistant patients
(Figure 2)[ 54]. Unlike pathogenic microbes, commensal
bacteria maintain a peaceful relationship with their hosts by
producing a transient activation of the NF-κBc a s c a d eo ri t s
suppression by diverse mechanisms including (i) promotion
of nuclear export of NF-κB subunit relA in complex
with PPAR-γ [55], (ii) inhibition of IκB ubiquitination
and degradation in epithelial cells [56], (iii) regulation of
TLR expression and upregulation of the negative regulator
Tollip protein [57], and (iv) induction of anti-inﬂammatory
cytokines such as IL-10 [58]. TLRs and derived cytokines
also play a pivotal role in linking innate and adaptive
immunitythroughexertingactiononT-cellsandparticularly
on dedritic cells (DCs), keeping a physiological Th1/Th2
balance [13]. Th1-polarized responses characterized by
overproduction of IFN-γ, IL-2, and IL-12 cytokines are
associated with clearance of intracellular pathogens as well
as with chronic diseases including diabetes and obesity. Most
TLR-activated DCs induce diﬀerentiation of na¨ ıve CD4+
T cells into Th1 cells, while TLR2-activated DCs promote
the diﬀerentiation of Th2-cells or regulatory T cells by
producing high levels of anti-inﬂammatory cytokine IL-10
which could help to counteract the inﬂammatory status
associated with obesity [58]. Interestingly, TLRs have been
identiﬁed not only in innate and adaptive immune cells6 Interdisciplinary Perspectives on Infectious Diseases
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Figure 2: Schematic diagram of signaling pathways triggered by bacterial components, saturated fatty acids, and adipokines in epithelial
and innate immune cells leading to either activation or negative regulation of proinﬂammatory pathways related to obesity and insulin
resistance. (1) Lipopolysaccharide (LPS) from Gram-negative bacteria and saturated fatty acids (SFAs) is recognized by toll-like receptor
(TLR) 4 activating proinﬂammatory pathways involving the MyD88 (myeloid diﬀerentiation primary-response protein 88)-dependent and
-independent pathways that may lead to activation of nuclear factor (NF)-κB and activator protein-1 (AP-1) with production of pro-
inﬂammatory cytokines. (2) Peptidoglycan (PGL) and lipoteichoic acid from Gram-positive bacteria are recognized by TLR-2 triggering
the activation of the MyD88-dependent pathway. (3) Commensal bacteria and some probiotics may suppress activation of NF-κBc a s c a d eb y
(i) promotion of nuclear export of NF-κB subunit relA in complex with PPAR-γ; (ii) inhibition of IκB ubiquitination and degradation, (iii)
induction of anti-inﬂammatory (IL10) cytokine production. (4) Leptin interacts with its receptors (OBR) activating the signal transducer
and activator of transcription (STAT), and induces production of CCL2, proinﬂammatory cytokines, and reactive oxygen species (ROS)
causing endoplasmic reticulum (ER) stress.
but also in insulin-responsive tissues such as the adipose
tissue, muscle, and liver, suggesting a connection between
immunity, microbial stimulation, and metabolism [59].
Diet-induced and genetically obese mice (ob/ob or db/db)
showedasigniﬁcantupregulationofexpressionofTLR-1to-
9inadipocytesandpreadipocytesalongwithhighercytokine
production upon stimulation [60]. In particular, it is known
thatTLR-4canbeactivatedbybothlipopolysaccharide(LPS)
and dietary-saturated fatty acids inducing upregulation of
common intracellular inﬂammatory pathways, such as JNK
and NF-κB in adipocytes and macrophages, related to
the induction of insulin resistance and increased adiposity
(Figure 2)[ 51]. Conversely, adipocyte-speciﬁc knockdown
of TLR4 prevented cytokine expression induced either by
LPS or saturated fatty acids and similar eﬀects were shown
in macrophages. With some exceptions, loss-of-functional
mutation in TLR-4 also prevented diet-induced obesity
and insulin resistance in vivo mice models [51]. Recently,
metabolic endotoxaemia, characterized by an increase in
serum LPS levels, has been demonstrated to be an inﬂam-
matory factor, causative of body weight gain, insulin resis-
tance, and diabetes in high-fat fed animal models [27,
61]. In contrast, the inhibition of the gut microbiota by
antibiotic administration (norﬂoxacin and ampicillin) in
two diﬀerent mouse models of insulin resistance resulted in
reduced serum LPS levels, low-grade inﬂammation, obesity,
and type-2 diabetes, demonstrating the link between the
gut microbiota and certain metabolic disorders [15]. LPS
stimulation also produces a cytokine-mediated increase in
plasma lipid levels by increasing the synthesis of VLDL
lipoproteins in the liver and inhibiting lipoprotein lipase. In
fact, mobilization of lipid stores is considered a mechanism
to fuel the host’s response against infections; moreover,
lipoproteins also seem to help ﬁght against infection byYolanda Sanz et al. 7
binding and neutralizing LPS [62]. Therefore, common
responses can be induced by “pathogenic lipid nutrients”
and microorganisms mainly related to TLR-4-signaling and
proinﬂammatory cytokine and gene transcription activation
pathways. In this scenario, one can hypothesize that shifts
in gut microbiota composition caused by a high-saturated
fatty acid-containing diet [27], together with dietary lipids,
could constitute synergic TLR signals, thus contributing
to the ampliﬁcation of inﬂammation occurring in obesity.
Consequently, it has been suggested that probiotics and
prebiotics with anti-inﬂammatory properties could be of
help in the ﬁght against obesity and associated disorders,
as reported in other chronic inﬂammatory diseases [53].
Although few speciﬁc studies have proven such a hypothesis
sofar,theadministrationoftheprobioticVSL3#wasdemon-
strated to exert a preventive eﬀect against type-1 diabetes
in a nonobese diabetic mice model by immunomodulatory
mechanisms, inducing IL-10 production in Peyer patches,
and spleen and its expression in the pancreas [63]. In
addition, Lactobacillus culture-supernatants were shown to
reduce in vitro leptin production by adipocytes, thereby
reducing IFN-γ production by lymphocytes and exerting
an anti-inﬂammatory role [64]. Oral administration of a
functional food product containing L. plantarum 299v to
heavy smokers for six weeks led to a decrease in leptin,
systolic blood pressure, and ﬁbrinogen, which was attributed
to the anti-inﬂammatory eﬀects of this probiotic, suggesting
it would be able to reduce cardiovascular risk [65]. In
contrast, oral administration of Lactobacillus acidophilus and
Biﬁdobacterium longum strains to human subjects did not
inﬂuence serum leptin levels [66]. The administration of a
prebiotic (oligofructose) to high-fat-diet fed mice was also
shown to restore Biﬁdobacterium levels, which positively
correlated with improved glucose tolerance, glucose-induced
insulin secretion, and normalization of inﬂammatory tone
by decreasing endotoxaemia in plasma and proinﬂammatory
cytokines in adipose tissue [27].
5. CONCLUSIONSAND FUTURE CHALLENGES
Gut microbes are viewed as novel factors involved in host
physiology and body weight regulation by driving a number
of metabolic and immune functions. The initial association
of the microbial colonization process of the germ-free
intestine with body weight gain conferred a negative role to
gut microbes with respect to obesity. Further, relationships
established between a speciﬁc microbiota structure and
a lean or obese phenotype have suggested that diﬀerent
microbes may inﬂuence body weight diﬀerently, and species-
and stain-speciﬁc functions are being deﬁned. In addition,
endotoxaemia and dysbiosis have been identiﬁed as inﬂam-
matory factors responsible for insulin resistance and body
weight, thereby returning to the concept that a healthy
microbiota may be beneﬁcial in preventing these disorders.
Although the cause-eﬀect relationships of the gut microbiota
with obesity remain unclear and a limited number of in vivo
trialshavebeendonetoassesstheeﬀectsofspeciﬁcmicrobial
strains (commensals and probiotics), and prebiotics on
metabolicdisorders,theknowledgeprovidedbythesestudies
constitutes a breakthrough in the identiﬁcation of their
etiology. Further work based on systems biology coupled
with “omic” technologies (metagenomics, trancriptomics,
and metabolomics) will be critical to shed light on the roles
of speciﬁc sets of microbes on metabolic disorders, with
a view to design more eﬃcient dietary-based strategies to
reduce their risk.
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